- Home
- FULC
FULC
Fulcrum Therapeutics Inc.
as 05-30-2025 4:00pm EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | 2019 |
| Target Price: | $6.29 | AVG Volume (30 days): | 903.4K |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.31 - $10.13 | Next Earning Date: | 05-01-2025 |
| Revenue: | $80,000,000 | Revenue Growth: | 3087.25% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Fulcrum Therapeutics Inc. (FULC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tourangeau Greg | FULC | Principal Accounting Officer | May 8 '25 | Sell | $5.06 | 498 | $2,519.88 | 14,062 |
Latest Fulcrum Therapeutics Inc. News
FULC Breaking Stock News: Dive into FULC Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory
GlobeNewswire
2 days ago
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
GlobeNewswire
2 days ago
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
MT Newswires
8 days ago
Fulcrum Therapeutics Shares Rise After Upgrade From Leerink
MT Newswires
8 days ago
Leerink Upgrades Fulcrum Therapeutics to Outperform From Market Perform, Adjusts Price Target to $12 From $4
MT Newswires
16 days ago
Fulcrum Therapeutics Shares Rise After Cantor Fitzgerald Upgrade
MT Newswires
16 days ago
Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight From Neutral, Price Target is $10
GlobeNewswire
22 days ago
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare FULC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FULC Fulcrum Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.